SCHEMBL16446539

SCHEMBL16446539

COC(=O)c1ccc(-n2ccc3c(C)nc(-c4ccc(Cl)s4)nc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.40
▸ PTK2 Q05397 1/20 0.38
▸ PDE4D Q08499 3/20 0.37
▸ HTT P42858 1/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ DHODH Q02127 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ FOS P01100 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446575 0.88 PDE4B (0.48) PDE4BPTK2PDE4DHTTPOLB
SCHEMBL16446537 0.82 ALDH1A1 (0.43) PDE4BPTK2HTTFGFR1POLB
SCHEMBL16446725 0.76 PTK2 (0.39) PDE4BPTK2HTTFGFR1POLB
SCHEMBL17950335 0.76 CSNK2A1 (0.46) PDE4BPDE4DHTTKDM4EALDH1A1
SCHEMBL16446446 0.75 PDE4B (0.50) PDE4BPTK2HTTFGFR1POLB
SCHEMBL16446601 0.74 PTK2 (0.43) PDE4BPTK2HTTFGFR1POLB
SCHEMBL16446770 0.73 PDE4B (0.59) PDE4BPTK2PDE4DHTTALDH1A1
SCHEMBL16446329 0.72 PDE4B (0.54) PDE4BPTK2HTTFGFR1POLB
SCHEMBL13779210 0.69 PRF1 (0.49) KDM4EALDH1A1MAPTMEN1LMNA
SCHEMBL17941882 0.68 CSNK2A1 (0.49) PDE4BPDE4DKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885PTK2 4064/4885PDE4D 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback